ESR1 and breast carcinoma: The results of cytopathology analysis for hormone-responsiveness biomarkers among 16 breast cancer patients without sugary indicated 12 (75 %) patients were with estrogen (ER)-positive, 13 (81.3%) patients with progesterone (PR)-positive, and 4 (25%) patients with HER2-positive; whereas, among 16 breast cancer patients with surgery, 13 (81.3%) patients were estrogen (ER)-positive, 10 (62.5) % patients were progesterone (PR)-positive, and 4 (25%) patients were HER2-positive (Table 2).